| TOTAL: $213.95M | ||||
| Year to Date: $863.65M | ||||
| Company | Partner | Amt. | Triggering | Details (Date) |
| (Symbol)#* | (Country) | (M) | Event | |
| Ardea Biosciences Inc. (IBPI) | Valeant Pharmaceuticals International Inc.(NYSE:VRX) | $0.5 | Milestone payment | Ardea received its first payment of $500,000 from Valeant for the selection of several pre-IND candidates from a family of potassium-channel openers that Ardea had been optimizing (8/16) |
| EPIX Pharmaceuticals Inc. (EPIX) | GlaxoSmithKline plc | $3 | Milestone payment | EPIX achieved a milestone under which it has identified three lead candidates that will move forward into lead optimization in the G-protein coupled receptor discovery program (8/14) |
| EPIX Pharmaceuticals Inc. (EPIX) | Cystic Fibrosis Foundation Therapeutics Inc. | $0.5 | Milestone payment | EPIX received a $500,000 payment for successfully identifying a hit compound that corrects the functionality of the cystic fibrosis transmembrane conductance regulator ion channel in a cell-based model system (8/28) |
| Indevus Pharmaceuticals Inc. (IDEV) | Esprit Pharma Inc. | $49.9 | Milestone payment | Indevus received the payment following the FDA approval of Sanctura XR (trospium chloride extended-release capsules) for treating overactive bladder (8/13) |
| Regeneron Pharmaceuticals Inc. (REGN) | Bayer HealthCare AG (Germany) | $20 | Milestone payment | For the recent initiation of a Phase III trial of VEGF Trap-Eye in the neovascular form of wet age-related macular degeneration (8/14) |
| Tripos Discovery Research Ltd. (OTC BB:TRPS) | Gemin X Biotechnologies Inc.* | ND | Milestone payment | In relation to the companies' January 2006 agreement; it results from the identification of a lead preclinical candidate for a Gemin X program in the study of ligands to prevent a telomeric DNA/protein interaction implicated in cancer (8/7) |
| Viropro International Inc. (Canada; OTC BB:VPRO) | Intas Biopharmaceuticals Ltd (India) | $0.05 | Milestone payment | Viropro received $50,000 as a down payment toward the first milestone payment in their agreement for the production of an undisclosed protein therapeutic (8/22) |
| Vivus Inc. (VVUS) | KV Pharmaceutical | $140 | Milestone payment | Vivus received a $140M milestone payment as part of a deal for the licensing rights for the menopause drug Evamist (estradiol) (8/9) |
| Notes: | ||||
| # Unless otherwise indicated, shares are traded on the Nasdaq exchange. * Private company. Currency conversions are based on exchange rates at the time of the deal. ND = Not disclosed. OTC BB = Over-the-Counter Bulletin Board.
| ||||
To read more on related topics, click on one of the words below.